<\/span><\/p>\n <\/span><\/p>\n <\/span><\/p>\n <\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=“1″ _builder_version=“4.16″ _module_preset=“default“ background_color=“#eef2f9″ da_disable_devices=“off|off|off“ global_colors_info=“{}“ theme_builder_area=“post_content“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_row _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n To achieve this ambitious goal, OPTIMA has brought together 36 partners from across 13 countries to:<\/strong><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=“1_3,1_3,1_3″ module_id=“nomarginbottom“ _builder_version=“4.16″ _module_preset=“default“ custom_padding=“||4px|||“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“1_3″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ custom_css_main_element_last_edited=“on|tablet“ custom_css_main_element_tablet=“margin-bottom:0 !important;“ custom_css_main_element_phone=“margin-bottom:0 !important;“ theme_builder_area=“post_content“]<\/p>\n Establish a secure, large-scale evidence data platform for prostate, breast and lung cancer that includes real-world data from more than 200 million people. With a focus on patient privacy, the platform will be GDPR-compliant. The interoperable platform will host datasets, data analysis tools, federated learning tools, AI algorithms and electronic decision support tools.<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=“1_3″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ custom_css_main_element_last_edited=“on|tablet“ custom_css_main_element_tablet=“margin-bottom:0 !important;“ custom_css_main_element_phone=“margin-bottom:0 !important;“ theme_builder_area=“post_content“]<\/p>\n Drive new knowledge generation by developing advanced analytics and AI models to identify, prioritise and fill the main knowledge gaps in prostate, breast and lung cancer \u2013 and propose improved clinical guideline recommendations.<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=“1_3″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n Develop AI-based decision support tools that can be employed in electronic health records (EHRs). These tools will help clinicians make care decisions based on the leading clinical practice guidelines for prostate, breast and lung cancer.<\/span><\/p>\n \u00a0<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=“1″ custom_padding_last_edited=“on|tablet“ admin_label=“Diagramm“ _builder_version=“4.23.1″ _module_preset=“default“ custom_margin_tablet=“0px||||false|false“ custom_margin_phone=““ custom_margin_last_edited=“on|tablet“ custom_padding=“||0px|||“ custom_padding_tablet=“0px||0px||false|false“ custom_padding_phone=““ hover_enabled=“0″ da_disable_devices=“off|off|off“ global_module=“4083″ saved_tabs=“all“ collapsed=“off“ global_colors_info=“{}“ theme_builder_area=“post_content“ disabled_on=“on|on|on“ disabled=“on“ sticky_enabled=“0″ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_row _builder_version=“4.16″ _module_preset=“default“ max_width=“1920px“ module_alignment=“center“ custom_margin=“||0px||false|false“ custom_padding=“||0px||false|false“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text disabled_on=“off|off|on“ module_id=“marginopen“ _builder_version=“4.16″ _module_preset=“default“ text_orientation=“right“ width=“100%“ module_alignment=“right“ custom_margin=“|30px|||false|false“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=“1″ admin_label=“Popup – #popwp“ module_id=“popwp“ module_class=“popup single“ _builder_version=“4.23.1″ _module_preset=“default“ custom_margin=“0px||0px||false|false“ custom_padding=“0px||0px||false|false“ hover_enabled=“0″ da_is_popup=“on“ da_popup_slug=“popwp“ da_is_singular=“on“ da_disable_devices=“off|off|off“ global_module=“4084″ saved_tabs=“all“ global_colors_info=“{}“ theme_builder_area=“post_content“ disabled_on=“on|on|on“ disabled=“on“ sticky_enabled=“0″ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_with_loader=“off“ da_has_shadow=“on“][\/et_pb_section][et_pb_section fb_built=“1″ _builder_version=“4.23.1″ _module_preset=“default“ da_disable_devices=“off|off|off“ global_colors_info=“{}“ theme_builder_area=“post_content“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_row _builder_version=“4.23.1″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.23.1″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_image src=“https:\/\/www.optima-oncology.eu\/wp-content\/uploads\/optima-diagramm-overview.png“ alt=“OPTIMA diagramm overview“ title_text=“OPTIMA diagramm overview“ show_in_lightbox=“on“ _builder_version=“4.23.1″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=“1″ _builder_version=“4.16″ _module_preset=“default“ custom_padding=“||138px|||“ da_disable_devices=“off|off|off“ global_colors_info=“{}“ theme_builder_area=“post_content“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_row _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n These new tools and models could allow for the processing of high-dimensional data across sources and the use of deep learning to identify factors that enable individualised, real-time care decisions \u2013 ultimately informing personalised treatment for patients with solid tumours. <\/p>\n The OPTIMA consortium consists of 36 multidisciplinary private and public stakeholders in the clinical, academic, patient, regulatory, data sciences, legal and ethical and pharmaceutical fields \u2013 and is being jointly led by Prof. Dr James N\u2019Dow from the European Association of Urology and Academic Urology Unit at the University of Aberdeen and Dr Hagen Kr\u00fcger, Medical Director Oncology, Pfizer Germany. [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row module_class=“testimonialbox“ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_testimonial author=“Prof. N\u2019Dow“ quote_icon=“off“ quote_icon_color=“#3AA1FF“ quote_icon_background_color=“#FFFFFF“ use_icon_font_size=“on“ icon_font_size=“48px“ _builder_version=“4.16″ _module_preset=“default“ author_text_color=“#7C88D8″ background_color=“RGBA(0,0,0,0)“ custom_padding=“|140px||140px|false|false“ custom_padding_tablet=“|80px||80px|false|true“ custom_padding_phone=“|20px||20px|false|true“ custom_padding_last_edited=“on|phone“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n \u201cOPTIMA\u2019s main objective is to harness the potential of AI to enable healthcare professionals to provide the most optimal personalised care for each individual patient living with prostate, breast and lung cancer and their families. This is an ambitious goal and one that the entire OPTIMA consortium is dedicated to delivering, building on the diverse knowledge base and expertise of our consortium members. By working together, we hope to deliver meaningful improvements in cancer care.\u201d<\/span><\/p>\n [\/et_pb_testimonial][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=“4.16″ _module_preset=“default“ custom_padding=“0px|||||“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n ARTTIC is proud to be part of this Consortium and project.<\/p>\n With its diverse multidisciplinary membership, the OPTIMA consortium is uniquely positioned to develop healthcare evidence-generation practices for the incorporation of real-world evidence into clinical practice guidelines (CPGs). If successful, OPTIMA may also help to establish best practice procedures for CPG development that incorporate analytics and evidence informed by AI models.<\/span><\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row module_class=“testimonialbox“ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_testimonial author=“Dr Kr\u00fcger“ quote_icon=“off“ quote_icon_color=“#3AA1FF“ quote_icon_background_color=“#FFFFFF“ use_icon_font_size=“on“ icon_font_size=“48px“ _builder_version=“4.16″ _module_preset=“default“ author_text_color=“#7C88D8″ background_color=“RGBA(0,0,0,0)“ custom_padding=“|140px||140px|false|false“ custom_padding_tablet=“|80px||80px|false|true“ custom_padding_phone=“|20px||20px|false|true“ custom_padding_last_edited=“on|phone“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n \u201cWhile healthcare has begun to take advantage of AI to improve treatment for patients with cancer, there is still immense untapped potential to integrate these next-generation tools into care models and decision-making. We hope that OPTIMA will be a key driver in the development of personalised treatments that recognize each patient\u2019s individual needs.\u201d<\/span><\/p>\n [\/et_pb_testimonial][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=“4.16″ _module_preset=“default“ custom_padding=“0px|||||“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n OPTIMA is at the forefront of healthcare innovation in Europe, building on other IMI projects (such as EHDEN, PIONEER and Harmony) that are supporting the European Health Data Space (EHDS) \u2013 a European Commission initiative to promote better exchange and access to different types of health data to support healthcare delivery and health research and policy. If it is successful, OPTIMA could not only contribute knowledge and data to the EHDS, but may also inform European policy regarding the clinical deployment of AI algorithms in healthcare.<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row module_class=“testimonialbox“ _builder_version=“4.16″ _module_preset=“default“ custom_margin=“|auto|9px|auto||“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_testimonial author=“Dr Pierre Meulien“ job_title=“Executive Director IMI“ quote_icon=“off“ quote_icon_color=“#3AA1FF“ quote_icon_background_color=“#FFFFFF“ use_icon_font_size=“on“ icon_font_size=“48px“ _builder_version=“4.16″ _module_preset=“default“ author_text_color=“#7C88D8″ position_text_color=“#7C88D8″ background_color=“RGBA(0,0,0,0)“ custom_padding=“|140px||140px|false|false“ custom_padding_tablet=“|80px||80px|false|true“ custom_padding_phone=“|20px||20px|false|true“ custom_padding_last_edited=“on|phone“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n \u201cThe OPTIMA project brings together experts from a wide range of disciplines and organisations. It is therefore well placed to potentially deliver results that could fast-track the use of artificial intelligence in the care of people with cancer.\u201d<\/span><\/p>\n [\/et_pb_testimonial][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=“1″ _builder_version=“4.16″ _module_preset=“default“ background_color=“#eef2f9″ da_disable_devices=“off|off|off“ global_colors_info=“{}“ theme_builder_area=“post_content“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_row _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n OPTIMA Consortium Members*:<\/strong><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=“1_3,1_3,1_3″ _builder_version=“4.16″ _module_preset=“default“ custom_padding=“||1px|||“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“1_3″ module_id=“nomarginbottom1″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ custom_margin_tablet=“||0px||false|false“ custom_margin_phone=““ custom_margin_last_edited=“on|tablet“ custom_padding_tablet=“||0px||false|false“ custom_padding_phone=““ custom_padding_last_edited=“on|tablet“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n Abbvie [\/et_pb_text][\/et_pb_column][et_pb_column type=“1_3″ module_id=“nomarginbottom2″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ custom_margin_tablet=“||0px||false|false“ custom_margin_phone=““ custom_margin_last_edited=“on|tablet“ custom_padding_tablet=“||0px||false|false“ custom_padding_phone=““ custom_padding_last_edited=“on|tablet“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n Erasmus Universitair Medisch Centrum Rotterdam [\/et_pb_text][\/et_pb_column][et_pb_column type=“1_3″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“]Oxford University Press contact<\/strong> Project office <\/strong> [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=“1″ disabled_on=“on|on|off“ admin_label=“Admin – do not delete“ _builder_version=“4.16″ _module_preset=“default“ da_disable_devices=“off|off|off“ global_colors_info=“{}“ theme_builder_area=“post_content“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_row _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_blurb use_icon=“on“ image_icon_width=“40px“ content_max_width=“70px“ admin_label=“WP Button “ module_class=“wpclose wpbuttonxx “ _builder_version=“4.16″ _module_preset=“default“ transform_rotate=“0deg|0deg|45deg“ positioning=“absolute“ position_origin_a=“top_right“ width=“100%“ max_width=“70px“ height=“70px“ max_height=“70px“ icon_font_size=“40px“ global_colors_info=“{}“ theme_builder_area=“post_content“][\/et_pb_blurb][et_pb_code _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n![\"\"](\"https:\/\/www.optima-oncology.eu\/wp-content\/uploads\/icon-enlarge.png\"){kind=icon}
<\/a><\/p>\n
<\/span><\/p>\n
Amgen CH
Arttic Innovation
Association EISBM
Bayer AG
CASUS, Helmholtz-Zentrum Dresden – Rossendorf
European Association of Urology
European Cancer Patient Coalition
European Institute of Oncology
European Lung Foundation
European Organisation for Research and Treatment of Cancer
European Respiratory Society<\/p>\n
German Cancer Society
GMV Soluciones Globales de Internet SAU
Helios Klinikum Emil von Behring
Institut de Cancerologie de l\u2019Ouest
Institut Universitari d\u2019Investigacio en Atencio Primaria
Information Technology for Translational Medicine
Ludwig-Maximilians-University Munich
Lund University
Maastricht University
Owkin<\/p>\n
\nQueen Mary University of London
\nPfizer
\nRoche CH
\nSmartReporting GMBH
\nThe University of Tartu
\nThe University Court of the University of Aberdeen
\nttopstart
\nUniversity College London
\nUniversity of Vienna
\nUniversita Vita-Salute San Raffaele
\nUppsala University
\nYDEAL software[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_button button_url=“@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjEyNCJ9fQ==@“ button_text=“Go to Consortium“ button_alignment=“center“ _builder_version=“4.16″ _dynamic_attributes=“button_url“ _module_preset=“default“ custom_margin=“50px||||false|false“ custom_margin_tablet=“0px||||false|false“ custom_margin_phone=““ custom_margin_last_edited=“on|tablet“ global_colors_info=“{}“ theme_builder_area=“post_content“][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=“1″ _builder_version=“4.16″ _module_preset=“default“ custom_padding=“3px||0px|||“ da_disable_devices=“off|off|off“ global_colors_info=“{}“ theme_builder_area=“post_content“ da_is_popup=“off“ da_exit_intent=“off“ da_has_close=“on“ da_alt_close=“off“ da_dark_close=“off“ da_not_modal=“on“ da_is_singular=“off“ da_with_loader=“off“ da_has_shadow=“on“][et_pb_row _builder_version=“4.16″ _module_preset=“default“ custom_padding=“99px||77px|||“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“]OPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the European Union\u2019s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
\nIMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
\nThe views communicated within are those of OPTIMA. Neither the IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_column type=“4_4″ _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“][et_pb_text _builder_version=“4.16″ _module_preset=“default“ global_colors_info=“{}“ theme_builder_area=“post_content“]<\/p>\n
Teresa Gro\u00df, ARTTIC Innovation GmbH: ![\"\"](\"https:\/\/www.optima-oncology.eu\/wp-content\/uploads\/email.png\")
gross@arttic-innovation.de<\/a><\/p>\n
Emma Jane Smith, European Association of Urology: e.smith@uroweb.org<\/a>
Femke van Diggelen, ttopstart: femke@ttopstart.com<\/a><\/p>\n